Apricus Biosciences, Inc.
Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros® and Erectile Dysfunction Population
SAN DIEGO, 2016-05-03 13:01 CEST (GLOBE NEWSWIRE) --
Presentation Speaker will be Edward D. Kim, M.D., Professor, The University of Tennessee Graduate School of Medicine
Vitaros U.S. NDA Re-Submission Remains on Schedule for 2H 2016
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced it will host a Vitaros®and erectile dysfunction (“ED”) key opinion leader event on Monday, May 9th, from 11:00 a.m. to 12:00 noon ET.
The meeting will feature a presentation by Edward D. Kim, M.D., Professor, Division of Urology at The University of Tennessee Graduate School of Medicine, Knoxville, TN. Dr. Kim will address the current status of treatment options in the ED population, unmet patient need based on contraindications or suboptimal response to currently available systemic treatments, provide an overview of the clinical data for Vitaros, and discuss where a non-systemic, topical treatment in the ED patient population may add value.
A live webcast with presentation slides and subsequent replay of the event will be available atwww.apricusbio.com. If you would like to ask a question during the live Q&A, please submit your request via email email@example.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. To participate by telephone, please dial (877) 841-3961 (Domestic) or (201) 689-8589 (International). The conference ID number is 13633850. The archived webcast will remain available for 30 days following the live presentation.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus’ commercial product, Vitaros®, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in several countries in Europe. In September 2015, Apricus in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus’ marketing partners for Vitaros include Laboratoires Majorelle, Bracco S.p.A., Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals), Mylan NV and Elis Pharmaceuticals Ltd. Apricus currently has one active product candidate, RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon.
For further information on Apricus, visithttp://www.apricusbio.com.
*Vitaros®is a registered trademark of NexMed International Limited. Such trademark is registered in certain countries throughout the world and pending registration in the United States.
CONTACT: Institutional / Retail Investors: Matthew Beck
The Trout Group LLC
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Nasdaq OMX
PwC24.10.2017 08:01 | pressemeddelelse
Corporate R&D spending hits record highs for the Top 1000, despite concerns of economic protectionism
Fallbrook Technologies24.10.2017 02:27 | pressemeddelelse
TEAM Industries Announces New Innovative Transmission Incorporating Fallbrook's NuVinci® CVP Technology
Telix Pharmaceuticals Limited24.10.2017 01:02 | pressemeddelelse
Telix Pharmaceuticals and ANMI Partner for Prostate Cancer Imaging
Telix Pharmaceuticals Limited23.10.2017 23:02 | pressemeddelelse
Telix Pharmaceuticals Limited Launches $50 Million Underwritten Initial Public Offering (ASX: TLX)
Brookfield Asset Management Inc23.10.2017 17:05 | pressemeddelelse
Brookfield Asset Management Notice of 2017 Q3 Results Conference Call and Webcast
Rapid Micro Biosystems23.10.2017 13:02 | pressemeddelelse
Rapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for Vaccines
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum